Fundamental Analysis of Rani Therapeutics Holdings Inc - Growth / Value Index


RANI - Valuation Highlights

Valuation Analysis

   Tsr Value Index - Very Poor Score of 5.00
   Price to Book Ratio of 4.02 suggesting that it is very expensive
   Book Value in last 3 years is trending down
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning -4.06 -3.73 8.14 %
Price to Book 3.63 5.23 211.48 % 9.35
Price to Sales 48.79 0 0 %
Enterprise Value to EBITDA Multiple -2.55 -5.18 -17.43 %


RANI - Profitability Highlights

Profitability Analysis

   Company's Profit Before Tax is increasing for last 5 Quarters
   Tsr Profitability Index - Very Poor Score of 5.00
   Piotroski F Score - Very Poor Value of 0.0
   Very Low Dividend Yield of 0 %
   Negative Net profit for last two years
   Company Net profit is Negative for last 5 Quarters
   In the last three years, the company has given poor Net Margin
   In the last three years, the company has given poor Returns on Equity
   In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity -178.56 -277.15 -233.93 % -101.15
Return On Asset -45.72 -61.57 -117.44 % -13.98
Net Profit Margin -1202.95 0 0 % 0
Operating Profit Margin -2313.35 0 0 % 0
EBITDA Margin -2305.09 0 0 % 0


Highlights
Market Cap137306 K
Enterprise Value161541 K
Price/Book TTM3.63
Outstanding Share26303.90 K
Float/ Outstanding Share52.07%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No0
Peter Lynch Ratio0
Piotroski F Score0
Altman Z Score-0.115
Sloan Ratio0.306
Peter Lynch Fair Value0


RANI - Growth Highlights

Growth Analysis

   Tsr Growth Index - Very Poor Score of 5.00
   Quarterly sales in last 5 Quarter is trending down
   Annual sales in last 3 years is trending down
   Company's Total Assets is Decreasing for last 3 years
   Operating Cash Flow decreasing for last 3 year
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 2750.00 K % 100.00 %
Gross Profit -1402.00 K 37.35 % 9.25 %
EBITDA -63390.00 K 5.13 % 6.26 %
Net Profit -33081.00 K 16.58 % 5.42 %
EPS -1.29 8.86 % NA


RANI - Stability Highlights

Stability Analysis

   Cash ratio of 6.08
   Tsr Stability Index - Very Poor Score of 5.00
   Altman Z Score of 0.157 suggest high risk
   Company has high debt burden
   Company is unable to generate enough free cash to support the business.
   Interest Coverage of -6.91
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 2.34 185.92 % 4.14
Cash Ratio 6.08 -70.29 %
Quick Ratio 0 0 % 3.09
Shareholders Equity 22.21 -34.89 %
Debt to EBITDA -0.991 5.05 %


Historical Valuation Ratios of Rani Therapeutics Holdings Inc

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Rani Therapeutics Holdings Inc

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Rani Therapeutics Holdings Inc

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Rani Therapeutics Holdings Inc

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)